# Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX

> **NCT03555123** · PHASE3 · UNKNOWN · sponsor: **Yooyoung Pharmaceutical Co., Ltd.** · enrollment: 112 (estimated)

## Conditions studied

- Acute Decompensated Heart Failure

## Interventions

- **DRUG:** Simdax

## Key facts

- **NCT ID:** NCT03555123
- **Lead sponsor:** Yooyoung Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-11
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-07-30
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03555123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03555123, "Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03555123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*